A 42-year-old woman from Delhi presents with heavy menstrual bleeding for the past 8 months. She reports soaking 10–12 pads per day during menses, with clots the size of a coin. Her cycles are regular (28 days), but duration has increased from 5 to 7 days. She denies intermenstrual bleeding, postcoital bleeding, or pelvic pain. On examination, the uterus is uniformly enlarged, firm, and mobile. Pelvic ultrasound shows a 4 cm intramural fibroid in the fundus and normal endometrial thickness (8 mm). Hemoglobin is 9.2 g/dL. What is the most appropriate first-line medical management?

Explanation

## Clinical Context This patient has **menorrhagia** (heavy menstrual bleeding) secondary to a **submucosal/intramural fibroid**. She is symptomatic with iron-deficiency anemia (Hb 9.2 g/dL) but is hemodynamically stable and desires uterine preservation. ## Rationale for Correct Answer: Tranexamic Acid **Key Point:** Tranexamic acid is a first-line **medical** agent for menorrhagia, particularly when the uterus is structurally abnormal (fibroids, adenomyosis) but the patient is not yet ready for or does not desire surgical intervention. **Mechanism:** Tranexamic acid is an antifibrinolytic that inhibits plasminogen activation, reducing fibrinolysis within the endometrium. It reduces menstrual blood loss by 25–50% and is most effective when taken during the menstrual period only. **Dosing:** 1.5 g (3 × 500 mg tablets) three times daily for 3–5 days during menses. **Advantages:** - Non-hormonal; does not require contraception - Minimal systemic side effects - Can be used long-term - Rapid onset (effective within 1–2 cycles) - Cost-effective **High-Yield:** Tranexamic acid is the **single most effective non-hormonal agent** for menorrhagia and is recommended as first-line by FIGO and RCOG guidelines before considering surgical or more invasive options. ## Why Other Options Are Not First-Line Here | Option | Why Not First-Line | Context | |--------|-------------------|----------| | **LNG-IUD** | Effective but requires insertion; patient has large fibroid (4 cm intramural). Risk of expulsion or malposition; reserved for adenomyosis or as second-line if medical therapy fails. | Second-line after medical therapy | | **GnRH agonist** | Causes hypoestrogenia (hot flushes, bone loss); used only short-term (3–6 months) as a bridge to surgery or to reduce fibroid size preoperatively. Not first-line for symptom control alone. | Preoperative adjunct, not primary therapy | | **Hysterectomy** | Definitive but irreversible; reserved for women who have completed childbearing and failed conservative therapy. Patient is 42 and no mention of completed family; not appropriate as first-line. | Last resort | ## Management Algorithm ```mermaid flowchart TD A[Menorrhagia + Fibroid]:::outcome --> B{Patient desires fertility?}:::decision B -->|Yes| C[Medical therapy first]:::action B -->|No| D[Consider surgical options]:::action C --> E[Tranexamic acid or NSAIDs]:::action E --> F{Adequate response?}:::decision F -->|Yes| G[Continue medical therapy]:::action F -->|No| H[Add LNG-IUD or consider myomectomy]:::action D --> I[Myomectomy vs hysterectomy]:::action ``` **Clinical Pearl:** Tranexamic acid works best when the endometrium is intact and bleeding is primarily from abnormal vascular architecture (as in fibroids). It is less effective in adenomyosis alone but still useful as part of combination therapy.